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Abstract 
Background: O u r   p u r p o s e   w a s   t o   i n v e s t i g a t e   t h e   c l i n i c a l   o u t c o m e s   o f   Z o t a r o l i m u s - and 
Paclitaxel-e l u t i n g   s t e n t s   i n   T u r k i s h   p a t i e n t s   w i t h   c o r o n a r y   a r t e r y   d i s e a s e   ( C A D ) .   I n   g e n e r a l ,  
the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. 
However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in 
unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes 
of these two drug-eluting stents in the real-world. 
Methods: We created a registry and prospectively analyzed data on a consecutive series of 
all  patients  who  presented  to  our  institution  with  symptomatic  coronary  artery  disease 
between February 2005 and March 2007 and who were treated with the zotarolimus- o r   t h e  
paclitaxel-eluting stent. The follow-up period was approximately two years. The primary 
end-point  was  major  cardiac  events,  and  the  secondary  end-point  was  definite  stent 
thrombosis. Informed consent was obtained from all subjects, and the study protocol was 
approved by the local ethical committee. 
Results: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 
116) or the paclitaxel-e l u t i n g   s t e n t   ( n   =   1 0 1 ) .   T h e   l e s i o n s   i n   t h e   2   a r m s   o f   t h e   s t u d y   w e r e  
treated  similarly  by conventional technique. At 24-month  follow-up the paclitaxel-eluting 
stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 
0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft 
surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). 
Conclusions: Zotarolimus-eluting stents demonstrated better clinical outcomes than Pac-
litaxel-eluting stents in a daily routine practice of coronary intervention in an unselected 
Turkish population. 
Key words: coronary artery disease, drug-eluting stent, major adverse cardiac event, stent throm-
bosis. 
INTRODUCTION 
In  prospective  randomized  controlled  trials, 
drug-eluting stents (DESs) have significantly reduced 
the rates of restenosis and target lesion revasculariza-




(BMSs) in patients with symptomatic coronary artery 
d i s e a s e   o f   s i m p l e   t o   m o d e r a t e   c o m p l e x i t y   ( 1 -3).  The 
u s e   o f   t h e   Z o t a r o l i m u s -eluting stent (ZES; Medtronic 
V a s c u l a r ,   S a n t a   R o s a ,   C A )   f o r   t r eating single de novo 
lesions in patients with symptomatic coronary artery 
d i s e a s e   h a s   b e e n   e x a m i n e d   i n   t h e   f i r s t   f o u r   t r i a l s   o f   t h e  
ongoing  ENDEAVOR  clinical  trials  program.  The 
r e s u l t s   o f   t h e s e   i n i t i a l   t r i a l s   i n d i c a t e   t h a t   t h e   Z E S   i s  
safe and reduces the rates of clinical and angiographic 
restenosis in patients with symptomatic coronary ar-
t e r y   d i s e a s e   ( C A D ;   4 ) .   A l s o   t h e   s a f e t y   a n d   e f f i c a c y   o f  
Paclitaxel-eluting stent (PES; Taxus, Boston Scientific 
C o r p . ,   N a t i c k ,   M a s s a c h u s e t t s )   h a s   b e e n   e x a m i n e d   i n  
the Taxus I-V studies (5-9). However, the late clinical 
o u t c o m e   o f   Z E S   a n d   P E S   i n   u n s e l e c t e d   p a t i e n t s  
treated  in  daily  practice  remains  controversial.  The 
long-t e r m   s a f e t y   o f   D E S s   r e m a i n s   i n   q u e s t i o n   ( 1 0 -11). 
Despite  the  results  of  meta-analyses of randomized 
stud i e s   r e f u t i n g   t h e s e   c o n c e r n s   ( 1 2 ) ,   l a t e   s t e n t   t h r o m-
bosis remains a limitation of DES technology. There-
fore,  longer-term safety is a pressing concern when 
c o m p a r i n g   Z E S   w i t h   P E S ,   p a r t i c u l a r l y   g i v e n   t h e   d i f-
ferences  in  drug  release  kinetics.  The  longer-term 
ou t c o m e s   o f   T u r k i s h   p a t i e n t s   t r e a t e d   w i t h   Z E S   v e r s u s  
PES in  “real  world”  practice  are  not well  reported. 
F u r t h e r m o r e ,   w i t h   t h e   a d v e n t   o f   n e w   D E S   s y s t e m s ,   i t  
is important to elucidate any differences in efficacy 
and  safety  when  utilizing  the  currently  available 
D E S s .   T h e r e f o r e ,   w e   r e p o r t   t h e   t w o -year outcomes of 
unselected patients with CAD treated with either ZES 





The  study  population  consisted  of  217  patients 
who  had  undergone  coronary  Zotarolimus-  (n:116) 
( Z E S ;   M e d t r o n i c   V a s c u l a r ,   S a n t a   R o s a ,   C A )   o r   P a c l i-
taxel- (n:101) eluting stent (PES; Taxus, Boston Scien-
tific  Corp.,  Natick,  Massachusetts)  implantation  for 
CAD  from  February  2005  to  March  2007.  Patients 
were eligible for enrollment if there was symptomatic 
CAD or positive functional testing, and angiographic 
evidence of a target lesion stenosis of ≥   7 0   %   i n   a   ≥   2 . 0  
mm  vessel.  Patients  with  a  contraindication  to  an-
tithrombotic therapy were excluded from the study. 
The control coronary angiographies were performed 
when there was evidence of ischemia. The follow-up 
p e r i o d   w a s   a p p r o x i m a t e l y   t w o   y e a r s .   I n f o r m e d   c o n-
s e n t   w a s   o b t a i n e d   f r o m   a l l   s u b j e c t s ,   a n d   t h e   s t u d y  
protocol was approved by the local ethical committee. 
Medications and Percutaneous Coronary Inter-
vention (PCI) Procedure 
All  patients  were  pretreated  with  aspirin  and 
clopidogrel.  A  loading  dose  of  300  mg  clopidogrel 
was administered  before  the  procedure  for  patients 
who were not previously pretreated with asprin and 
clopidogrel.  During  the  procedure,  a  bolus  dose  of 
unfractionated  heparin  (100  U/kg)  was  injected 
t h r o u g h   t h e   f e m o r a l   o r   r a d i a l   a r t e r y   s h e a t h ,   w i t h   r e-
peated boli administered as needed to maintain acti-
v a t e d   a n d   c l o t t i n g   t i m e   o f   2 5 0   t o   3 0 0   s .   P a t i e n t s   r e-
ceived intracoronary nitroglycerin (0.1 to 0.2 mg) to 
achieve  maximal  vasodilatation  before  undergoing 
their initial and final angiograms. The glycoprotein 
IIb/IIIa inhibitor (Tirofiban) was administered at the 
operator’s  discretion.  All  patients  maintained  an-
ti-platelet  therapy  following  the  procedure  (aspirin 
3 0 0   m g / d   f o r   3   m o n t h s   a n d   1 0 0   m g / d   i n f i n i t e l y ;   c l o-
p i d o g r e l   7 5   m g / d   f o r   6   t o   1 2   m o n t h s ) .   T h e   P C I   p r o-
cedure  and  stent  implantation  were  performed 
through a femoral or radial approach using standard 
m e t h o d s .   T h e   o p e r a t o r s   w e r e   f r e e   t o   use the stent ap-
proach and either the ZES or PES stent that they con-
sidered to be best.  
Study End Points and Definitions 
The primary clinical efficacy end points included 
m a j o r   a d v e r s e   c a r d i a c   e v e n t s   ( M A C E )   a t   t w o   y e a r  
(MACE:  Death,  myocardial  infarction,  target  vessel 
revascularization (TVR). Target vessel revasculariza-
t i o n   w a s   d e f i n e d   a s   b e i n g   e i t h e r   p e r c u t a n e o u s   o r   s u r-
gical revascularization of the stented epicardial vessel. 
The secondary end-point was definite stent thrombo-
sis (acute, <1 day; subacute, 1 to 30 days; late, >30 
d a y s   a n d   v e r y   l a t e ,   > 1   y e a r ) .   M y o c a r d i a l   i n f a r c t i o n  
was defined as a creatine kinase (CK) elevation >2 
times above the upper limit of normal levels with any 
associated elevation in the CK myocardial band or the 
development of new pa t h o l o g i c   Q   w a v e s   i n   2   c o n t i-
guous electrocardiographic leads. Myocardial infarc-
tion  and  stent  thrombosis  definitions  used  in  this 
study were consistent with the newest consensus of 
the Academic Research Consortium (13). All primary 
and secondary clinical en d   p o i n t s   w e r e   a d j u d i c a t e d   b y  
an independent clinical events committee blinded to 
the patient’s treatment assignment. 
Follow-up 
Clinical follow-up was performed at 1, 6, 12, and 
2 4   m o n t h s   b y   t e l e p h o n e   c o n t a c t   o r   o f f i c e   v i s i t s .   R e l e-
vant data were collected a n d   e n t e r e d   i n t o   a   c o m p u t e-
rized database by specialized personnel at the cardi-





All  statistical  analyses  were  performed  with 
S P S S   f o r   W i n d o w s   ( v e r s i o n   1 0 . 0 ,   C h i c a g o ,   U S A ) .  
Continuous  variables  were  d e s c r i b e d   a s   m e a n   ±  
standard  deviation  (SD),  and  categorical  variables 
were  reported  as  percentages  or  proportions.  Com-
p a r i s o n   o f   c o n t i n u o u s   v a r i a b l e s   w a s   p e r f o r m e d   w i t h  
unpaired  t-tests  (normal  distribution)  and  nonpara-
metric Mann-Whitney U test (skew distribution). Ca-
tegorical variables were analyzed using Fisher’s exact 
test  and  chi-square  test.  We  used  Kaplan-Meier 
time-to-event estimates for the primary events at the 
two-year  follow-up,  and  compared  the  difference 
b e t w e e n   t h e   Z E S   a n d   t h e   P E S   t r e a t e d   g r oups with the 
Kaplan-M e i e r   m e t h o d   a n d   l o g -rank test. A P value < 
0.05 was considered statistically significant. 
RESULTS 
Baseline clinical, coronary angiographic and le-
s i o n   c h a r a c t e r i s t i c s   a r e   s h o w n   i n   T a b l e   1   a n d   T a b l e   2 .  
No significant differences were present in the baseline 
clinical  or  demographic  characteristics  between  pa-
tients receive ZES versus PES. Baseline angiographic 
characteristics were similar according to the modified 
ACC/AHA  (American  College  of  Cardiology  / 
American  Heart  Association)  classification  (14). 
Overall, most lesions were located in the left anterior 
descending artery and were of the B1 and C type. The 
median stent for the ZES treated group was 31±4 mm 
in diameter and 31±5 mm (p: 0.8) for the PES treated 
group. Additionally, the median  stent  length  in  the 
Z E S   t r e a t e d   g r o u p   w a s   2 6 ± 4   m m   c o m p a r e d   t o   2 8 ± 8  
mm (p: 0.2) in the PES treated group.  
Table 1. Age and Baseline Clinical Characteristics of Pa-
tients by Treatment Cohort 





Age, mean (SD), yc   60 (9.2)  58 (10.2)  .2 
History, No. (%)       
Diabetes mellitus  54 (46)  36 (36)  .7 
Hypertension  76 (65)  64 (63)  .5 
History of smoking  69 (59)  55 (54)  .4 
Hyperlipidemia  84 (72)  69 (68)  .5 
Prior MI  8 (7)  7 (7)  .4 
Prior PTCA  8 (7)  6 (6)  .2 
Prior CABG  6 (5)  3 (3)  .3 
SAP   36 (31)  34 (34)  .6 
USAP  52 (44)  47 (47)  .2 
MI  28 (25)  20 (20)  .4 
Serum concentrations, mean (SD), 
mg/dL 
   
Total cholesterol  228.8 (50.49  233.8 (57.4)  .8 
LDL  146.3 (48.8)  150.3 (48.4)  .5 
HDL  38.2 (6.5)  39.4 (8.3)  .5 
Triglyceride  160.1 (101.7)  158.6 (101.2)  .8 
Glucose  127.2 (62.7)  114.7 (46.4)  .2 
Abbreviations: CABG, coronary artery bypass graft; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; MI, myo-
cardial infarction; SAP, stable angina pectoris; USAP, unstable 
angina pectoris. 
aIndicates patients who received zotarolimus-eluting stents. Num-
bers in the column do not total 100% because some patients had 
more than one condition. 
bIndicates patients who received paclitaxel-eluting stents. Numbers 
in the column do not total 100% because some patients had more 
than one condition. 
cP < 0.05 defined as statistically significant. 
 
Table 2. Baseline Angiographic Characteristics  
  Zotarolimusa 
(n:116) 
Paclitaxelb (n:101) P Valuec 
Site of Lesion Treated, No. (%)     
LAD  81 (70)  76 (75)  .369 
Cx   18 (15)  9 (9)  .056  
RCA   17 (15)  16 (16)  .506 
LVEFd,e    68.7 (5.7)  67.4 (7.3)  .6 
Stent diameter, 
mme 
31 (4)  31 (5)  .8 
Stent length, mme  26 (4)  28 (8)   .2 
Lesion length, 
mme 
21 (3)  22 (7)  .1 
Type of lesion, No. (%)     
 A   3 (3)  2 (2)  .9 
 Bı   52 (45)  47 (46)  .9 
 B2   12 (10)  11 (11)  .8 
 C   49 (42)  41 (41)  .9 
Abbreviations: Cx, left circumflex coronary artery; LAD, left ante-
rior descending coronary artery; LVEF, left ventricular ejection 
fraction; RCA, right coronary artery. 
aIndicates patients who received zotarolimus-eluting stents. 
bIndicates patients who received paclitaxel-eluting stents. 
cP < 0.05 defined as statistically significant. 
dReported as percentage. 
eData expressed as mean (SD). 
 
In-hospital outcomes 
In-hospital outcomes were similar between ZES 
a n d   P E S   t r e a t e d   g r o u p s .   I n   h o s p i t a l   i n c i d e n c e   o f  
MACE was 1.7% in ZES treated group and 1.9% in 
PES treated group (p:0.6).  
Long-term clinical outcomes 
Two-year clinical follow-ups were completed for 
2 1 4   p a t i e n t s .   A t   t h e   e n d   o f   t h e   t w o   y e a r s ,   t h e   i n c i d e n c e  
o f   M A C E   i n   t h e   g r o u p   t r e a t e d   w i t h   Z E S   w a s   1 0 %   a n d  
17.8% (p:0.003) was recorded for the group treated 
w i t h   P E S .   T h e   i n c i d e n c e   o f   C A B G   ( 2 . 6 %   v s   6 . 9 % ,  
p:0.002), Q-wave myocardial infarction (1.7% vs 5.9%, 
p:0.049) and non Q-wave myocardial infarction (2.6% 
v s   5 . 9 % ,   p : 0 . 0 2 )   w a s   s i g n i f i c a n t l y   h i g h e r   i n   t h e   P E S  
treated group. There were no major differences in the 
r a t e s   o f   d e a t h   ( p : 0 . 7 ) ,   t a r g e t   v e s s e l   r e v a s c u l arization 




(p:0.3).  Additionally,  the  incidence  of  late  stent 
thrombosis was significantly higher in the PES treated 
group  (1.7% vs  3.9%,  p:0.046)  at 24  months.  There 
were  no  major  differences  in  the  incidence   o f   a c u t e  
(0.9% vs 0.9%, p:1.0), subacute (1.7% vs 3.9%, p:0.06) 
and very late stent (0.9% vs 0.9%, p:0.7) thrombosis in 
the ZES and PES groups. (Table 3) 
 
Table 3 Comparison of Secondary End Points by Cohort 
  No. (%)   







Acute   1 (0.9)  1 (0.9)  1.0 
Subacute  2 (1.7)  4 (3.9)  .06 
Late  2 (1.7)  4 (3.9)  .046 
Very late  1 (0.9)  1 (0.9)  .7 
aIndicates patients who received zotarolimus-eluting stents. Per-
centages in this column are based on a cohort of 116 patients. 
bIndicates patients who received paclitaxel-eluting stents. Percen-
tages in this column are based on a cohort of 101 patients. 
cP < 0.05 defined as statistically significant.  
 
Discussion  
We demonstrate in this study that, the treatment 
of  CAD  using  ZES  in  an  unselected  population  of 
Turkish patients over a 24-month period, resulted in a 
significantly lower incidence of major adverse cardiac 
events, CABG and definite stent thrombosis then the 
PES. T h e   s a f e t y   a n d   e f f i c a c y   o f   Z E S   and PES had pre-
viously been examined in ENDEAVOR and TAXUS 
trials  (3-9,  15-17)  respectively,  however,  due  to  dif-
f e r e n c e s   i n   t r i a l   d e s i g n   o r   a n   e m p h a s i s   o n   a n g i o-
graphic rather than clinical end points, clinical trials 
comparing the safety and efficacy between these DES 
types and BMSs have yielded inconsistent results. In 
the  ENDEAVOR  I,  II,II  Continued  Access  Registry 
( C A )   a n d   I I I   t r i a l s   ( 1 5 ,   3 ,   1 6 ,   1 7 ) ,   t h e   r a t e   o f   M A C E  
r a n g e d   f r o m   3 . 1 % , t o   1 2 . 8 % ,   a t   t h e   e n d   o f   t h e   t w o -year 
p e r i o d .   I n   o u r   t r i a l ,   h o w e v e r ,   t h e  incidence of MACE 
i n   t h e   Z E S   t r e a t e d   g r o u p   w a s   1 0 %   a t   t h e   e n d   o f   t h e  
two year follow-up (Table 4). Additionally, the inci-
d e n c e   o f   Q   w a v e   M I   r a n g e d   f r o m   0 %   t o   0 . 3 %   i n   t h e  
f i r s t   f o u r   E N D E A V O R   t r i a l s   c o m p a r e d   t o   1 . 7 %   i n   o u r  
Z E S   t r e a t e d   g r o u p .   O n   t h e   o t h e r   h a nd, the incidence 
of non-Q   w a v e   M I   r a n g e d   f r o m   1 % ,   t o   5 . 6 %  in first 
four ENDEAVOR trials whilst registering at 2.6% in 
t h e   Z E S   t r e a t e d   g r o u p   i n   o u r   t r i a l .   T h e   r e s u l t s   o f   t h e  
f i r s t   4   E N D E A V O R   t w o -y e a r   t r i a l s   s u g g e s t e d   t h a t   Z E S  
is  safe  and  reduces  the  rates  of  clinical  and  angio-
graphic restenosis in an selected patients with symp-
tomatic coronary artery disease of simple to moderate 
complexity (4). Since the population used in our study 
was  an  unselected,  high-r i s k   g r o u p ,   f o u r   p a t i e n t s   i n  
the  ZES  treated  group  were  prematurely  taken  off 
their antiplatelet therapy and this likely played a role 
i n   t h e   o b s e r v e d   M A C E   e v e n t s .   A l s o   n o t e w o r t h y   w a s  
the observation that, the lesion and the stent lengths 
r e c o r d e d   i n   o u r   s t u d y   w e r e   s i g n i f i c a n t l y   l o n g e r   t h a n  
previously recorded for the four ENDEAVOR trials. 
 
Table 4. Clinical Outcomes at 24-Month Follow-up 
  No. (%)   







     
 Target vessel   5 (4.3)  5 (4.9)  0.6 
 Non target-vessel  4 (3.4)  4 (3.9)  0.3 
CABG n(%)  3 (2.6)  7 (6.9)  0.002 
 Myocardial infarction 
n(%) 
     
 Q-wave   2 (1.7)  6 (5.9)  0.049 
 Non-Q-wave  3 (2.6)  6 (5.9)  0.02 
Death n(%)  2 (1.7)  1 (0.9)  0.7 
MACE n(%)  12 (10)  18 (17.8)  0.003 
aIndicates patients who received zotarolimus-eluting stents. Per-
centages in this column are based on a cohort of 116 patients. 
bIndicates patients who received paclitaxel-eluting stents. Percen-
tages in this column are based on a cohort of 101 patients. 
cP < 0.05 defined as statistically significant. 
 
 
The  o u t c o m e   o f   o u r   s t u d y   o n   t h e   P E S   t r e a t e d  
p a t i e n t s   w e r e   a l s o   c o m p a r e d   t o   p r e v i o u s   s t u d i e s   i n  
which  the  TAXUS  trials  (TAXUS  1,  TAXUS  III, 
T A X U S   I V   a n d   T A X U S   V I   ( 5 ,   7 ,   8 ,   9 ) )   w e r e   u s e d .  
Whilst our study showed a MACE rate of 17.8% at the 
end of the two-y e a r   f o llow-up, the MACE rates for the 
T A X U S   t r i a l s   r a n g e d   f r o m   3 %   i n   T A X U S   I   t r i a l   ( 5 )   t o  
2 9 %   i n   t h e   T A X U S   I I I   t r i a l   ( 7 ) .   T h e   T A X U S   I V   t r i a l   ( 8 )  
represented a larger patient population and the rate of 
M A C E   w a s   1 0 . 8 % .   I n t e r e s t i n g l y   t h e   T A X U S   V I   t r i a l  
which was designed to show whether this benefit will 
b e   r e p r o d u c i b l e   i n   s u b s e t s   o f   t h e   p a t i e n t   p o p u l a t i o n  
with even more complex and long lesion lengths (9) 
r e g i s t e r e d   a   M A C E   r a t e   o f   2 1 . 3 % .   I t   s h o u l d   b e   n o t e d  
t h a t   t h e   T A X U S   V I   t r i a l   a n d   o u r   s t u d y   h a d   a   a t  
two-year  follow-u p   w h i l s t   r e s u l t s   f o r   t h e   o t h e r  
TAXUS  trials  represent  records  for  one-year  fol-
low-up. Seven patients in the PES treated group were 
prematurely  taken  off  their  antiplatelet  therapy  and 
this likely played a role in the observed MACE events. 
Additionally, the stent and lesion lengths recorded in 
o u r   s t u d y   w e r e   c o m p a r a b l e   w i t h   t h e   T a x u s   V I   p o p u-
lation  
To understand the safety and performance of the 
ZES and PES in the real-world patients, (patients not 
subject to any anatomic or clinical exclusion criteria) 




those seen in other trials, the E-Five Registry (18) and 
T a x u s   i n   R e a l -life Usage Evaluation (TRUE) program 
( 1 9 )   w e r e   e m p l o y e d   i n   p r e v i o u s   s t u d i e s .   T h i s   m u l t i-
c e n t e r   g l o b a l   r e g i s t r y   h a s   a n   e n r o l l m e n t   o f   8 , 3 1 8 pa-
tients  at  188  different  hospitals,  with  10,343  lesions 
treated. The in-hospital  rate  of  MACE  for  the  1,989 
p a t i e n t s   r e c e i v i n g   t h e   E n d e a v o r   Z E S   w a s   a s   l o w   a s  
1 . 1 % ,   w h i c h   i s   c o m p a r a b l e   w i t h   t h e   i n -hospital inci-
d e n c e   o f   M A C E   ( 1 . 7 % )   f o r   t h e   Z E S   t r e a t e d   g r o up  in 
o u r   s t u d y .   D e s p i t e   t h e   s m a l l   p o p u l a t i o n   s i z e   u s e d   i n  
o u r   s t u d y ,   o u r   r e s u l t s   c o n f i r m   t h e   i n -hospital rate of 
M A C E   o f   E -Five  Registry.  The  TRUE  trial  shares  a 
s i m i l a r   v a l u e   a s   t h e   E -Five Registry in that the patients 
were not subjected to any anatomic or clinical exclu-
sion criteria. In-h o s p i t a l   M A C E   o c c u r r e d   i n   3 . 7 %   p a-
t i e n t s   i n   t h e   T R U E   t r i a l   c o m p a r e d   t o   1 . 9 %   f o r   t h e   P E S  
treated group in our study.  
P r e v i o u s   s t u d i e s   h a v e   s h o w n   t h a t   a   p o t e n t i a l  
p r o b l e m   w i t h   t h e   D E S   i s   l a t e   i n -stent thrombosis (20). 
Multip l e   s t u d i e s   h a v e   s h o w n   t h a t   t h e   u s e   o f   a n t i-
platelet agents decreases the risk of in-stent thrombo-
s i s   i n   D E S   t r e a t e d   p a t i e n t s   a n d   h a v e   b e e n   u s e d   i n   m o s t  
of the trials described earlier. However when the an-
tiplatelet  therapy  used  in  these  trials  is  interrupted, 
in-stent thrombosis sets in (21-23). Consecutively the 
stent thrombosis rate at end of the two-year follow-up 
in first four ENDEAVOR I, II, IICA, III were 1%, 0,5%, 
0 % ,   0 % .   A l s o   i n   t h e   T a x u s   I   t r i a l ,   t h e   s t e n t   t h r o m b o s i s  
was 0% at one year, 0.6% in Taxu s   I V   a t   o n e   y e a r ,   0 . 5 %  
i n   T a x u s   V I   a t   t w o   y e a r .   C o m p a r a t i v e l y ,   t h e   i n c i d e n c e  
o f   l a t e   s t e n t   t h r o m b o s i s   i n   o u r   t r i a l   w a s   s i g n i f i c a n t l y  
h i g h e r   i n   t h e   P E S   t r e a t e d   g r o u p   ( 1 . 7 %   v s   3 . 9 % ,   p :  
0 . 0 4 6 )   a t   t h e   e n d   o f   t h e   t w o -year  follow-u p .   A l s o   i n  
o u r   s t u d y ,   n o   m a j o r  differences were observed in the 
incidence of acute (0.9% vs 0.9%, p: 1.0) and subacute 
( 1 . 7 %   v s   3 . 9 % ,   p :   0 . 0 6 )   s t e n t   t h r o m b o s i s   i n   t h e   Z E S  
c o m p a r e d   t o   t h e   P E S   t r e a t e d   g r o u p s .   A l l   t h e   p a t i e n t s  
in this study were placed on aspirin and clopidogrel 
after  stent implantation, as recommended, however, 
premature  elimination  of  the  antiplatlet  therapy  in 
addition to longer lesion and stent lengths and also 
the  high-risk  associated  with  an  unselected  patient 
population likely contributed to the stent thrombosis 
and MACE results observed in our study. 
Study Limitations  
T h e   s t u d y   h a s   s e v e r a l   l i m i t a t i o n s ,   t h e   m a i n   o n e s  
b e i n g   t h e   s m a l l   n u m b e r   o f   p a t i e n t s ,   l a c k   o f   d i r e c t  
randomisation  and  relatively  low  compliance  with 
angiographic follow-up. 
CONCLUSIONS 
B a s e d   o n   t h e   t w o-year  clinical  results  of  this 
study  it  is  reasonable  to  conclude  that  treatment  of 
unselected Turkish patients with Zotarolimus-eluting 
stent  is  more  effective  than  treatment  with  Paclitax-
el-eluting stent in unselected Turkish patients. 
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